2/2 Taiwan BIO Weekly
2026-02-02 |
| Taiwan BIO Weekly |
| Taiwan's strategic embrace of biotechnology (Includes video) 30 January, 2026 Faced by a challenging security environment, Taiwan is looking beyond its core semiconductor industry and cultivating biotech as a new strategic pillar. More... |
| ScinoPharm Taiwan successfully secures Taiwan approval for multiple myeloma treatment 30 January, 2026 ScinoPharm Taiwan (TW: 1789) announced that it has successfully obtained Taiwan regulatory approval from the Taiwan Food and Drug Administration (TFDA) for Bortezomib, a treatment for multiple myeloma. The company noted that it previously received US FDA approval for Bortezomib in 2023, and the newly granted Taiwan approval marks another major milestone. This achievement underscores ScinoPharm Taiwan's decades-long expertise in oncology drug development and aligns with the government's policy of strengthening supply chain resilience. The company is currently moving forward with applications for National Health Insurance (NHI) reimbursement, aiming to benefit more patients in Taiwan and to firmly anchor internationally recognized key manufacturing technologies and high-quality medicines domestically. More... (in Chinese) |
| T-E PHARMA plans stock listing with five new drugs under clinical development 30 January, 2026 T-E PHARMA, founded by renowned antibodies pioneer Chang Tse-Wen, aims to list on Taiwan's emerging stock market in 2026, marking its entry into the capital markets. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at key inflection points, including two that have advanced to Phase II clinical trials and three in late preclinical to early transitional stages, with first-in-human trial applications expected to be filed this year. T-E PHARMA's pipeline spans metabolic diseases, neuroendocrine tumors, thrombotic disorders, and cancer, supported by core platforms such as fatty-acid-modified peptides, multi-arm linkers, and ADC technologies. Key assets include Immunwork's ultra-long-acting GLP-1 drug TE-8105, now in Phase IIB, and TE-8214, a fatty-acid-modified octreotide analog in Phase II for neuroendocrine tumors and acromegaly, as the group evaluates international licensing, strategic partnerships, and capital-market strategies. More... (in Chinese) |
| YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership 29 January, 2026 YD Bio Limited (NASDAQ:YDES), announced it has entered into a binding letter of intent to acquire [Taiwan's] Safe Save Medical Cell Sciences Technology Co., Ltd., a move aimed at bolstering its leadership in advanced immunocell therapy. More... |
| Synmosa Biopharma secures Taiwan approval for IBAT inhibitor to treat chronic constipation 28 January, 2026 Synmosa Biopharma Group (TW: 4114) announced that Goofice, the world's first IBAT (Ileal Bile Acid Transporter) inhibitor for the treatment of chronic functional constipation, has received regulatory approval in Taiwan. The drug is expected to launch between April and June this year, offering a new treatment option for clinical practice. Licensed from EA Pharma of Japan, Goofice is the first IBAT inhibitor globally approved for chronic functional constipation. With its novel mechanism of action, the drug has demonstrated a favorable safety profile and sustained efficacy in improving bowel movement frequency, stool consistency, and quality of life. Synmosa noted that the drug has completed clinical trials at 10 medical centers and one regional hospital in Taiwan. More... (in Chinese) |
| Gongwin Biopharm Holdings achieves breakthrough with new horse tumor drug 28 January, 2026 Gongwin Biopharm Holdings (TW: 6617) announced that its investigational equine tumor drug p-TLS, targeting superficial tumors including melanoma, squamous cell carcinoma, and sarcoma, has shown outstanding efficacy, achieving a 100% tumor ablation rate in published safety and clinical trial data. More... (in Chinese) |
| Bora Pharmaceuticals Group expands San Diego facility 28 January, 2026 Bora Pharmaceuticals (TW: 6472) announced that its subsidiary, Tanvex BioPharma (TW: 6541), has officially completed the expansion of its San Diego facility. With stable order growth from international clients in its core business and the gradual benefits from its US subsidiary Upsher-Smith (USL) transformation, the group is entering a key growth phase powered by dual engines of small- and large-molecule operations. More... (in Chinese) |
| Lin BioScience's LBS-008 for Stargardt disease completes enrollment in DRAGON II Phase II/III trial 28 January, 2026 Lin BioScience (TW: 6696) announced on behalf of its subsidiary Belite Bio, that its LBS-008 (Tinlarebant) treatment for adolescent Stargardt disease (STGD1) has completed enrollment of 60 patients in the DRAGON II Phase II/III clinical trial across Japan, the US, and the UK. Belite plans to submit a New Drug Application (NDA) to the US FDA in the first half of 2026. The company further noted that 15 of the enrolled patients are from Japan, and the Japanese patient data will support future regulatory filings and commercialization plans in Japan. More... (in Chinese) |
| Taiwan launches new era of medical AI with global collaboration 28 January, 2026 The Health Ministry on Wednesday launched its new AI Compute Center and International Federated Learning Program, marking a major step towards integrating artificial intelligence into Taiwan's healthcare system. The initiative responds to the Cabinet's "New Ten Major AI Construction Projects," focusing on smart applications, core technologies, and digital infrastructure. More... |
| TaiGen's influenza drug enters South Korean market 27 January, 2026 TaiGen Biotechnology (TW: 4157) has licensed its antiviral drug Pixavir marboxil (TG-1000) to South Korea's Boryung Biopharma for exclusive marketing in that market, securing upfront, milestone, and royalty payments. With South Korea reporting a record 3+ million influenza cases in 2023 and a growing proportion of younger patients, existing treatments such as oseltamivir face adherence challenges due to five-day dosing requirements. As a single-dose therapy, Pixavir marboxil offers greater convenience and easier administration for children, positioning it to become a preferred option for physicians and parents in South Korea's expanding influenza market. More... (in Chinese) |
| StemCyte's umbilical cord blood new drug delivers dual upside 27 January, 2026 StemCyte (TW: 4178) announced that its umbilical cord blood therapy REGENECYTE has achieved two major milestones. First, Phase II clinical results for treating long COVID were officially published in eClinicalMedicine, a leading journal under The Lancet. Second, REGENECYTE for long COVID has received US FDA approval for an Expanded Access Program (EAP), with pricing already set, highlighting its strong commercial potential. More... (in Chinese) |
| Taiwan Bio Therapeutics achieves two major advances in regulatory T cell therapy 26 January, 2026 Taiwan Bio Therapeutics (TW: 6892) announced that it has achieved two major milestones in the field of regulatory T cells (Tregs). The company successfully recruited global T cell immunology authority Arlene Sharpe to its scientific advisory board and, together with Professors Sharpe and Peter Sage, led a collaborative study between Taiwan Bio Therapeutics, Harvard University, and Brigham and Women's Hospital (BWH), with the results published in the prestigious journal Nature Immunology. More... (in Chinese) |
| Taiwan's PharmaEssentia gains US recognition for rare blood disorder drug 26 January, 2026 Taiwan's PharmaEssentia announced Sunday that its drug Ropeg has been recommended in the US National Comprehensive Cancer Network (NCCN) treatment guidelines as a therapy for high-risk essential thrombocythemia, a rare blood disorder. Essential thrombocythemia (ET) causes the body to produce too many platelets, increasing the risk of blood clots, heart attacks, and strokes, according to Cleveland Clinic. NCCN guidelines cover care for over 97% of people in the US affected by or at risk for cancer and are updated regularly to reflect the latest research and treatment advances, according to NCCN. More... |
| ========================================= |
| Taiwan Bio Industry Organization (Taiwan BIO) Tel: +886 2 27836028 Fax: +886 2 27836027 Email: biotaiwan@gmail.com BIO Asia-Taiwan 2026 (15-19 July, 2026) ========================================= Taiwan Bio Industry Organization (Taiwan BIO) Room C229, 2F, Bldg. C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei, Taiwan (11571) ========================================= |